stoxline Quote Chart Rank Option Currency Glossary
  
Precision BioSciences, Inc. (DTIL)
9.74  -0.98 (-9.14%)    04-19 16:00
Open: 10.51
High: 10.84
Volume: 170,483
  
Pre. Close: 10.72
Low: 9.5224
Market Cap: 67(M)
Technical analysis
2024-04-19 5:08:58 PM
Short term     
Mid term     
Targets 6-month :  15.77 1-year :  18.65
Resists First :  13.5 Second :  15.97
Pivot price 13.43
Supports First :  9.52 Second :  7.92
MAs MA(5) :  11.57 MA(20) :  13.21
MA(100) :  12.21 MA(250) :  14.65
MACD MACD :  -0.4 Signal :  0.1
%K %D K(14,3) :  3.6 D(3) :  13.1
RSI RSI(14): 32.8
52-week High :  27.89 Low :  8.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ DTIL ] has closed below the lower bollinger band by 8.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ DTIL ] is to continue within current trading range. It is unclear right now based on current values. 60% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.91 - 11.02 11.02 - 11.08
Low: 9.32 - 9.44 9.44 - 9.52
Close: 9.6 - 9.8 9.8 - 9.92
Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Headline News

Wed, 17 Apr 2024
Precision BioSciences (NASDAQ:DTIL) Rating Reiterated by HC Wainwright - MarketBeat

Tue, 16 Apr 2024
Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration (NASDAQ:DTIL) - Seeking Alpha

Tue, 16 Apr 2024
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Business Wire

Thu, 11 Apr 2024
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance

Wed, 27 Mar 2024
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates - Zacks Investment Research

Wed, 27 Mar 2024
Precision BioSciences: Q4 Earnings Snapshot - WRAL News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 7 (M)
Shares Float 5 (M)
Held by Insiders 8.4 (%)
Held by Institutions 39.8 (%)
Shares Short 289 (K)
Shares Short P.Month 49 (K)
Stock Financials
EPS -332.12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.53
Profit Margin -125.9 %
Operating Margin -211.6 %
Return on Assets (ttm) -13.8 %
Return on Equity (ttm) -107.3 %
Qtrly Rev. Growth -33.6 %
Gross Profit (p.s.) 0
Sales Per Share 7.04
EBITDA (p.s.) -5.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -84 (M)
Levered Free Cash Flow -50 (M)
Stock Valuations
PE Ratio -0.03
PEG Ratio 0
Price to Book value 2.15
Price to Sales 1.38
Price to Cash Flow -0.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android